Acrivon Therapeutics (NASDAQ:ACRV) Earns Overweight Rating from Analysts at KeyCorp

KeyCorp assumed coverage on shares of Acrivon Therapeutics (NASDAQ:ACRVFree Report) in a research report report published on Friday morning, MarketBeat Ratings reports. The brokerage issued an overweight rating on the stock.

ACRV has been the subject of several other reports. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Acrivon Therapeutics in a research report on Thursday, November 14th. BMO Capital Markets lowered their target price on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Acrivon Therapeutics currently has an average rating of “Buy” and an average target price of $23.67.

Read Our Latest Report on Acrivon Therapeutics

Acrivon Therapeutics Price Performance

NASDAQ ACRV opened at $6.07 on Friday. The company has a 50 day simple moving average of $6.34 and a 200-day simple moving average of $7.33. Acrivon Therapeutics has a 52-week low of $3.19 and a 52-week high of $11.90. The firm has a market capitalization of $189.02 million, a price-to-earnings ratio of -2.25 and a beta of 0.77.

Institutional Trading of Acrivon Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. State Street Corp raised its holdings in Acrivon Therapeutics by 26.4% during the 3rd quarter. State Street Corp now owns 225,896 shares of the company’s stock worth $1,581,000 after buying an additional 47,233 shares during the period. Exome Asset Management LLC acquired a new stake in shares of Acrivon Therapeutics during the third quarter worth $817,000. JPMorgan Chase & Co. lifted its position in Acrivon Therapeutics by 548.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock valued at $238,000 after acquiring an additional 28,748 shares in the last quarter. Barclays PLC boosted its stake in Acrivon Therapeutics by 51.2% in the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock worth $233,000 after purchasing an additional 11,273 shares during the period. Finally, Dimensional Fund Advisors LP bought a new position in Acrivon Therapeutics during the 2nd quarter worth about $58,000. Institutional investors and hedge funds own 71.62% of the company’s stock.

About Acrivon Therapeutics

(Get Free Report)

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

Featured Articles

Analyst Recommendations for Acrivon Therapeutics (NASDAQ:ACRV)

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.